NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors

Novo NordiskNovo Nordisk has announced that NovoSeven® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in people with haemophilia A or B with inhibitors.(1) Efficacy also remained high for bleeds treated after 4 hours. (1) A subanalysis of the SMART-7™ study, evaluating the efficacy of NovoSeven® in a real-world setting, was presented today at the 58th American Society of Haematology (ASH) annual meeting.

The SMART-7™ study examined the status of bleeding episodes across people with haemophilia divided into three groups by time to first treatment with NovoSeven® (≤1 hour, ˃1‒≤4 hours, ˃4 hours).(1) Across the three groups, 94.6% of bleeds were resolved while another 4.8% of bleeds were slowed.(1)

"Clinical guidelines recommend that acute bleeds in people with haemophilia should be treated within two hours of bleed onset," said Dr Gary Benson, SMART-7™ investigator, Northern Ireland Haemophilia Comprehensive Care Centre, Belfast City Hospital, Belfast, UK. "This study has shown that NovoSeven® has a favourable safety profile and can help people living with haemophilia to address bleeds quickly."

Efficacy results from this subgroup analysis of SMART-7™ are aligned with previous rFVIIa data.(2-7) Furthermore, no binding antibodies were associated with the room temperature stable formulation of rFVIIa under real-world conditions.

About SMART-7™
SMART-7™ (NCT01220141) was a prospective, post-authorisation, single-arm, multinational, multi-centre, non-interventional study investigating the safety and effectiveness of NovoSeven® (rFVIIa), a room temperature stable recombinant activated factor VIIa in people with haemophilia A or B with inhibitors in a real-world setting.(1)

A total number of 51 participants were enrolled across 14 countries. Participants were aged 1.6–69.5 years (median 22.0 years) with a historical median bleeding rate of one episode per month. The primary objective of the study was to monitor people with haemophilia A or B with inhibitors treated with NovoSeven® for a decreased therapeutic response.(1)

About NovoSeven® NovoSeven® is a recombinant activated factor VII (rFVIIa) and is indicated for the treatment of spontaneous and surgical bleedings in haemophilia A or B patients with inhibitors, acquired haemophilia, congenital FVII deficiency and Glanzmann's thrombasthenia (EU and US only).(8)

About haemophilia
Haemophilia is a chronic, inherited bleeding disorder that primarily affects males. People born with haemophilia have little or no clotting factor, which is a protein needed for normal blood clotting. The two main types of haemophilia are A and B; people living with haemophilia A lack clotting factor VIII and people living with haemophilia B lack clotting factor IX. Haemophilia A is about four times as common as haemophilia B.9 Inhibitor formation is the most serious complication in haemophilia A or B, rendering the patient unresponsive of replacement therapy with clotting factor VIII or IX. In that case, bypassing agents such as NovoSeven® are used.

Haemophilia can be mild, moderate or severe, depending on the amount of clotting factor in the blood. Approximately 400,000 people are estimated to live with haemophilia globally.(10)

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,600 people in 75 countries and markets its products in more than 180 countries.

1. Benson, G. et al. Benefit of early treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in patients with Hemophilia A or B with inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-interventional SMART-7™ Study. Poster number 1439. 58th American Society of Haematology (ASH) annual meeting. 3 December 2016.
2. Lusher JM. Eur J Haematol 1998;61(suppl 63):7–10.
3. Santagostino E, et al. Blood Rev 2015;29(suppl 1):S9–18.
4. Santagostino E, et al. J Thromb Haemost 2006;4(2):367–71.
5. Young G, et al. Haemophilia. 2008 Mar;14(2):287–94.
6. Kavakli K, et al. Thromb Haemost 2006;95(4):600–5.
7. Lentz SR, et al. J Thromb Haemost 2014;12(8):1244–53.
8. NovoSeven® Summary of Product Characteristics.
9. National Heart Lung and Blood Institute. What is hemophilia? https://www.nhlbi.nih.gov/health/health-topics/topics/hemophilia (last accessed October 2016).
10. National Hemophilia Foundation. Fast Facts. http://www.hemophilia.org/About-Us/Fast-Facts (last accessed November 2016).

Most Popular Now

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...